Goldmans M&A expert to join GSK
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Glaxosmithkline has appointed Goldman Sachs' leading European mergers and acquisition (M&A) banker, Simon Dingemans, as its finance director.
Mr Dingemans will replace Julian Heslop in March when he steps down. GSK said that Mr Dingemans, who is a partner managing director at the US investment bank, had 25 years' experience and had worked closely with the company in the past.
Andrew Witty, GSK's chief executive, said: "Simon will bring valuable experience and capability to support us in our strategy to grow and diversify GSK's business through organic means and bolt-on acquisitions. He will also be responsible for delivering cost savings from our global restructuring programme and implementing further measures to simplify our operational model."
Despite Mr Dingemans experience in high profile M&A deals, GSK has insisted it is chasing only smaller, bolt-on acquisitions.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments